PMID- 37150681
OWN - NLM
STAT- MEDLINE
DCOM- 20230513
LR  - 20230513
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 103
IP  - 17
DP  - 2023 May 9
TI  - [Effect of Liraglutide on platelet distribution width and carotid intima-media 
      thickness in type 2 diabetic mellitus patients with obesity].
PG  - 1316-1322
LID - 10.3760/cma.j.cn112137-20220924-02018 [doi]
AB  - Objective: To investigate the effect of Liraglutide on platelet distribution 
      width(PDW) and carotid intima-media thickness(cIMT) in type 2 diabetic mellitus 
      patients with obesity. Methods: Randomized controlled trial. A total of 80 type 2 
      diabetes mellitus (T2DM) obese patients with unsatisfactory glucose control were 
      prospectively enrolled in this study from the Department of Endocrinology of 
      Yuhuangding Hospital Affiliated to Qingdao University from January to December 
      2021. All the participants were treated with metformin or sulfonylureas. They 
      were randomly divided into two groups: Liraglutide treatment group (Li group, 
      n=40) and Control group (Con group, n=40).The Li group started the treatment with 
      Liraglutide on the basis of the original hypoglycemic agents and the Con group 
      was treated with metformin and sulfonylurea. After 16 weeks of treatment, the 
      changes of PDW, cIMT and body mass index (BMI) in the two groups were observed, 
      multiple linear regression was uesd to analyze the influencing factors of cIMT 
      variation, and the effect of liraglutide on PDW and cIMT in obese patients with 
      type 2 diabetes was analyzed. Results: Finally, 38 patients completed the study 
      in Li group, including 23 males and 15 females, aged 30-69(56+/-11) years. All 40 
      patients in Con group completed the study, including 18 males and 22 females, 
      aged 39-67(59+/-7) years. After 16 weeks of treatment, the levels of PDW and cIMT 
      in Li group were (12.8+/-1.6) fl and (0.85+/-0.08) mm, respectively, lower than those 
      before treatment (15.0+/-1.6) fl and (1.14+/-0.10) mm (t=18.61 and 20.37, 
      respectively, both P<0.001); The PDW and cIMT in Con group were (13.6+/-1.5) fl and 
      (1.05+/-0.10) mm, respectively, lower than those before treatment (15.0+/-1.5) fl and 
      (1.13+/-0.13) mm (t=17.42 and 9.65, respectively, both P<0.001). The levels of 
      fasting plasma glucose (FPG) and total cholesterol (TC) in both groups were lower 
      than those before treatment(all P<0.001). After the treatment, the levels of PDW, 
      cIMT, FPG and TC in Li group were lower than those in Con group (all P<0.05). The 
      changes of PDW and cIMT before and after the treatment in Li group were (2.2+/-0.7) 
      fl and (0.30+/-0.09) mm, respectively, higher than those in the Con group 
      [(1.4+/-0.5) fl and (0.09+/-0.06) mm], with a statistically significant difference 
      (both P<0.001). The changes of FPG and TC in Li group were significantly higher 
      than those in Con group (all P<0.05). Multiple linear regression analysis showed 
      that liraglutide, the changes of TC and systolic blood pressure (SBP) were the 
      influencing factors for the changes of cIMT [beta (95%CI) were 0.20 (0.17-0.23), 
      0.03 (0.01-0.06), 0.01 (0.00-0.01), respectively, all P<0.05] Conclusion: 
      Liraglutide treatment could reduce PDW and cIMT, thus contributing to 
      cardiovascular benefits.
FAU - Meng, X M
AU  - Meng XM
AD  - Department of Endocrinology, the Affiliated Yantai Yuhuangding Hospital of 
      Qingdao University, Yantai 264000, China.
FAU - Hao, Y P
AU  - Hao YP
AD  - Department of Endocrinology, the Affiliated Yantai Yuhuangding Hospital of 
      Qingdao University, Yantai 264000, China.
FAU - Yu, S
AU  - Yu S
AD  - Department of Endocrinology, the Affiliated Yantai Yuhuangding Hospital of 
      Qingdao University, Yantai 264000, China.
FAU - Ren, R Z
AU  - Ren RZ
AD  - Department of Endocrinology, the Affiliated Yantai Yuhuangding Hospital of 
      Qingdao University, Yantai 264000, China.
FAU - Yu, X
AU  - Yu X
AD  - Department of Endocrinology, the Affiliated Yantai Yuhuangding Hospital of 
      Qingdao University, Yantai 264000, China.
FAU - Tang, Y X
AU  - Tang YX
AD  - Department of Endocrinology, the Affiliated Yantai Yuhuangding Hospital of 
      Qingdao University, Yantai 264000, China.
LA  - chi
GR  - 2021YD016/Yantai Science and Technology Innovation Development Program/
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
RN  - 0 (Blood Glucose)
RN  - 839I73S42A (Liraglutide)
RN  - 9100L32L2N (Metformin)
RN  - 0 (Sulfonylurea Compounds)
SB  - IM
MH  - Female
MH  - Humans
MH  - Male
MH  - Blood Glucose
MH  - Carotid Intima-Media Thickness
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Liraglutide/therapeutic use
MH  - *Metformin/therapeutic use
MH  - Obesity
MH  - Sulfonylurea Compounds
EDAT- 2023/05/08 00:41
MHDA- 2023/05/09 06:42
CRDT- 2023/05/07 22:00
PHST- 2023/05/09 06:42 [medline]
PHST- 2023/05/08 00:41 [pubmed]
PHST- 2023/05/07 22:00 [entrez]
AID - 10.3760/cma.j.cn112137-20220924-02018 [doi]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2023 May 9;103(17):1316-1322. doi: 
      10.3760/cma.j.cn112137-20220924-02018.